drugset / Trial / NCT05537948
Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients
Phase 4
Active not recruiting
59 enrolled
National Medical Research Center for Therapy and Preventive Medicine
RandomizedParallel-groupDouble-blindTreatment
Summary
To study the efficacy and safety of pitavastatin and PCSK9 inhibitors in liver transplant patients on ongoing immunosuppressive therapy.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2024-01-31
- Completion
- 2025-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Alirocumab | Monoclonal antibody | 150 mg | Subcutaneous |
| Comparator | Evolocumab | Monoclonal antibody | 140 mg | Subcutaneous |
| Comparator | Pitavastatin | Small molecule | 4 mg | — |